Antimyelin Antibodies as a Predictor of Clinically Definite Multiple Sclerosis After a First Demyelinating Event
NEJM 349:139-145,107, Berger,T.,et al, 2003
Application of the New McDonald Criteria to Patients with Clinically Isolated Syndromes Suggestive of Mulitple Sclerosis
Ann Neurol 52:47-53, Dalton,C.M.,et al, 2002
Early Onset Multiple Sclerosis
Neurol 59:1006-1010, Boiko,A.,et al, 2002
Course and Prognosis in Early-Onset MS
Neurol 59:1922-1928, Simone,I.L., etla, 2002
Randomized Controlled Trial of Interferon-beta-1a in Secondary Progressive MS
Neurol 56:1496-1504, Secondary Progressive Efficacy Clinical Trial of R, 2001
Primary and Transitional Progressive MS,A Clinical and MRI Cross-Sectional Study
Neurol 52:839-845, Stevenson,V.L.,et al, 1999
Multiple Sclerosis in Children Under 6 Years of Age
Neurol 53:478-484, Ruggieri,M.,et al, 1999
Multiple Sclerosis That is Progressive From the Time of Onset, Clinical Characteristics and Progression of Disability
Arch Neurol 56:1138-1142, Andersson,P.B.,et al, 1999
Association Between Tumor Necrosis Factor-x and Disease Progression in Patients with Multiple Sclerosis
NEJM 325:467-472, Shareif,M.K.&Hentges,R., 1991
Patterns of Disease Activity in Multiple Sclerosis:Clinical and Magnetic Resonance Imaging Study
BMJ 300:631-634, Thompson,A.J.,et al, 1990
Multiple Sclerosis in Childhood:Clinical Profile in 125 Patients
J Pediatr 111:359-363, Duquette,P.,et al, 1987
Multiple Sclerosis After Age 50
Neurol 33:1537-1544, Noseworthy,J.,et al, 1983